The MICHAEL KORS SPRING 2015 EYEWEAR COLLECTION

The MICHAEL KORS SPRING 2015 EYEWEAR COLLECTION

Wednesday, March 18 2015 | 00 h 00 min | New Products

The Michael Kors Spring 2015 eyewear collection captures the glamour and effortless sophistication for which the designer is celebrated.

Including both sun and optical styles, the season’s highlights range from sleek cat-eye shapes to cool, classic aviators and bold, screen-siren geometrics, each designed with the designer’s signature jet set sensibility.

Front and center is the new Miranda Eyewear Collection, inspired by Michael Kors’ iconic Miranda handbag and combining luxury, craftsmanship and high-voltage glamour. Miranda, a name Kors says he chose because “it’s something both old-school glamorous and barefoot modern at once,” blends vintage allure with contemporary fashion, lending understated but unmistakable chic to any look. The temple detail is interpreted in three different materials— bold metals, brilliant stones, and luxe leathers—to evoke the three attitudes of the Michael Kors woman: sporty, sexy and glamorous.

Available through Luxottica. http://www.luxottica.com/en/eyewear-brands

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

The MICHAEL KORS SPRING 2015 EYEWEAR COLLECTION

Featured Posts